Bharat Biotech’s Covid-19 intranasal vaccine Phase III trials over, proven safe

Hyderabad, Aug 15: Bharat Biotech’s COVID-19 intranasal vaccine (BBV154) has proven to be safe, well-tolerated, and immunogenic in subjects in controlled clinical trials phase III. The vaccine candidate was evaluated earlier in phase I and II clinical trials with successful results. BBV154

Source: India News, India Breaking News, Latest news headlines in India – Oneindia News